Tag: Treatment management

Studies confirm that towards the end of a 3- to 4-week intravenous immunoglobulin (IVIG) treatment cycle, patients often experience a 'wear-off' effect characterized by decreased treatment efficacy. This phenomenon is a predictable consequence of the medication's average half-life (around 21-28 days) and the resulting drop in therapeutic immunoglobulin levels.

According to clinical trials, a significant number of patients on Esbriet experienced fatigue, with some studies reporting incidence rates as high as 26% compared to placebo groups. It's crucial for patients to understand if and **does Esbriet cause fatigue** and how to manage this side effect effectively.